Skip to content
Peptides Codex

Use the arrow keys to choose a result, Enter to open it, and Escape to close.

← Home
Quality

How to Read a Peptide COA (Certificate of Analysis)

Understand HPLC purity, mass spectrometry identity, net peptide content, TFA salts, and red flags on research peptide COAs.

By The Peptides Codex Editorial TeamIndividual review date not recorded

What a COA is for

A certificate of analysis documents analytical results for a specific batch. In research procurement, it is the primary trust artifact—more important than website photography or purity percentages in ads.

Identity: does the mass match?

Mass spectrometry (MS) should report a molecular ion consistent with the theoretical average or monoisotopic mass of the sequence (including expected modifications). A COA without identity testing is incomplete.

Purity: HPLC percentage

HPLC purity estimates the fraction of the main peak among detected peptide-related peaks under a method. “99%” is only meaningful with method details and a chromatogram. Different methods can yield different numbers.

Net peptide content

Lyophilized vials contain peptide plus counter-ions and residual water. Net peptide content (NPC) tells you how much actual peptide is present by weight. Dosing math in labs should use NPC, not just label weight.

TFA and salts

Many research peptides are trifluoroacetate salts from purification. TFA content can affect weight and, in sensitive biology, assay outcomes. Some vendors offer acetate exchange—document which salt form you received.

Red flags

Generic COAs reused across batches, missing lot numbers, no chromatogram, impossible masses, stock photos of spectra, or purity claims without dates. Independent third-party testing is the gold standard when stakes are high.

Selecting the compound lets the checker compare the document against published chemistry, not just against itself.

Paste a certificate above to see the checks.

Sources and what they cover

These primary studies, official records and standards cover the topics linked below. The scope notes distinguish laboratory findings, human trials and regulatory records. This is a selected bibliography, not a systematic review or verification of every sentence; absence of a study here does not prove that no study exists.

  1. ICH Q2(R2) — Validation of Analytical Procedures (FDA guidance)

    Analytical validation framework. A chromatogram alone does not validate identity, content, sterility or fitness for human use.

    Relevant sections: What a COA is for · Identity: does the mass match? · Purity: HPLC percentage · Net peptide content · Red flags

FAQ

Is 99% HPLC purity enough?+

It is only one data point. You also want identity confirmation, batch specificity, and preferably net peptide content. Method matters.

What is the difference between purity and content?+

Purity describes how clean the peptide peak is among related impurities. Content describes how much peptide is in the powder by mass versus salts and moisture.

Related peptide profiles

BPC-157
Research pentadecapeptide (gastric-juice-derived sequence)
BPC-157 (Body Protection Compound-157) is a synthetic 15-residue peptide, GEPPPGKPADDAGLV, derived from a sequence found in human gastric juice. Hundreds of rodent studies, most from a single Zagreb group, report accelerated healing of tendon, muscle, ligament, gut and skin injuries via VEGFR2, nitric-oxide and ERK1/2 pathways. Human evidence is limited to a small safety study and a retrospective chart review; the first phase 2 efficacy trial began recruiting in 2026. It is not approved anywhere and the FDA barred it from compounding in 2023.
TB-500
Synthetic thymosin β4 fragment (research peptide)
TB-500 is the synthetic, N-acetylated heptapeptide Ac-Leu-Lys-Lys-Thr-Glu-Thr-Gln (Ac-LKKTETQ), corresponding to residues 17–23 of thymosin β4, the protein's actin-binding motif. It first appeared as a veterinary preparation and is sold as a research chemical; its metabolism has been characterised in rats. A 2026 rat tendon study reported benefits with vendor-labelled TB-500 whose sequence was not characterized, so it does not establish efficacy of Ac-LKKTETQ. The fragment has no published human efficacy data. No product-specific authorization record has been verified in this profile; human trial registration does not establish approval. Its first registered human trial began recruiting in 2026.
Semaglutide
Incretin analog
Semaglutide is a 31-amino-acid GLP-1 receptor agonist peptide (C187H291N45O59, ≈4,114 Da). It keeps 94% of the human GLP-1 sequence but substitutes Aib at position 8 to block DPP-4 cleavage, replaces Lys34 with Arg, and attaches a C18 fatty diacid to Lys26 through a γ-glutamate and two OEG spacers so the peptide binds albumin. The result is a half-life of about 7 days and once-weekly dosing in the approved products Ozempic and Wegovy (and once-daily oral dosing as Rybelsus).
CJC-1295
Long-acting GHRH analogue (research compound)
CJC-1295 (C165H269N47O46, ≈3,647 Da) is a 30-residue analogue of growth hormone-releasing hormone(1-29) engineered by ConjuChem to bind serum albumin covalently after injection, extending its action from minutes to days. In healthy adults a single injection raised growth hormone 2- to 10-fold for six days or more and IGF-1 1.5- to 3-fold for 9–11 days, with an estimated half-life of 5.8–8.1 days. It was never approved: a phase 2 trial in HIV-associated visceral obesity was terminated, and it is now an unapproved research peptide prohibited in sport.

More guides

Disclaimer: Educational content only. Not medical advice. Not instructions for human use. Regulations vary by jurisdiction.
You might also like: All guides · Encyclopedia · Tools · FAQ
Cite this: Peptides Codex — How to Read a Peptide COA (Certificate of Analysis)
Tip: Use browser print (Ctrl/Cmd + P) for a clean PDF of this page.